Ocular Therapeutix Q3 loss widens as product revenue drops, costs rise
Overview
U.S. retinal disease drugmaker's Q3 product revenue declined yr/yr, net loss widened
Company increased R&D and marketing spend for clinical trials and pre-commercial investments
Cash balance of $530.6 mln as of Sept 30, 2026, expected to fund operations into 2028
Outlook
Ocular Therapeutix plans AXPAXLI NDA submission for wet AMD in 4Q 2026
Company to conduct interim SOL-R Week 52 safety analysis in 4Q 2026 for NDA submission
SOL-R topline primary endpoint results expected in 1Q 2028 after key secondary endpoints evaluated
Result Drivers
R&D SPENDING - Co said higher R&D expenses were driven by accelerated enrollment in HELIOS-3 diabetic retinopathy and SOL-X extension studies, as well as increased headcount and infrastructure for expanded clinical trial activity
PRE-COMMERCIAL INVESTMENTS - Co attributed higher selling and marketing expenses to increased personnel and investments to prepare for a potential AXPAXLI wet AMD launch
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Product Revenue | $12.87 mln | ||
Q3 Loss Per Share | $0.42 | ||
Q3 Net Loss | $94.78 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Ocular Therapeutix, Inc. is $28.00, about 324.6% above its November 6 closing price of $6.60
Reuters Recommended Reads
Nov 6 - UK's Immunocore Q3 loss misses estimates on higher R&D spending
Nov 7 - FDA probes tumour risk tied to Novartis gene therapy
Nov 7 - J&J's once-daily pill eases psoriatic arthritis symptoms in late-stage trial
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)